cardiac valvular disease
Conditions
Interventions
1:Genotype-based Warfarin Initiation
2:clinical factor-based warfarin initiation
Sponsors
The first affiliated hospital of Sun Yat Sen University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: All the included patient should be the first time to receive the mitral and/or aortic mechanical prosthetic valve repalcement. They should be willing to join in the clinical trial and comply with the protocol.
Exclusion criteria
Exclusion criteria: All the patients with the following criteria should be excluded:other ethics than Han; previously receive any other cardiac surgery; emergent surgery;simutaneously carry out other cardiac surgeries; age younger than 18y or older than 65y; drug abuser and wine abuser; any malignancy;any chronic hepatic or kidney disease; any thyroid disease; the history of warfarin or VitK consumption 2 week before the surgery; any hematological disease or history of bleeding; combination with any drugs that significantly influence warfarin other than Cordarone; pregnancy; any contraindication of warfarin; infectious endocarditis; advanced valvular disease; pathological obesity;psychological disease; any patient having joined in other clinical trial in the previous 30d; basic INR>1.4.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time to steady dosage;Time in Therapeutic Range; | — |
Secondary
| Measure | Time frame |
|---|---|
| first time to treatment window;the ratio of INR>=3.0 and INR<=1.5;the monitoring frequency of INR;the whole-cause mortality large bleeding event and large thrombosis rate; | — |
Contacts
Public ContactZhang Xi
Outcome results
None listed